Mochida Pharmaceutical Co., Ltd. (4534) AI Stock Analysis

• Market Cap: ¥100.32B
• Dividend Yield: 2.71%
• Average Volume (3M): 27.28K
• Price to Earnings (P/E): 17.3
• Beta (1Y): 0.54
• Revenue Growth: 2.74%
• EPS Growth: 36.86%
• Country: JP
• Employees: 1,522
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 53.43
• Shares Outstanding: 36,390,000
• 10 Day Avg. Volume: 28,480
• 30 Day Avg. Volume: 27,280
• PEG Ratio: 0.75
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 1.07
• P/FCF Ratio: 15.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: ¥3,191.00 ▲(3.27% Upside)

Mochida Pharmaceutical's overall stock score reflects strong financial stability and profitability, but is tempered by declining revenue growth and bearish technical indicators. The valuation is moderate, offering a reasonable dividend yield. Addressing revenue and cash flow challenges is crucial for future growth.

Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Mochida Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which include proprietary drugs and generic medications. The company benefits from a diversified revenue model that includes sales from both domestic and international markets. Key revenue streams come from the marketing of its proprietary drugs, which are developed through extensive research and clinical trials, as well as partnerships with other pharmaceutical companies for co-development and distribution. Additionally, Mochida engages in licensing agreements that allow it to earn royalties on its patented products. The company's consistent focus on innovation, coupled with strategic collaborations and a robust product pipeline, significantly contributes to its financial performance.

Mochida Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Mochida Pharmaceutical shows strong profitability and financial stability with low leverage, as evidenced by healthy profit margins and a robust balance sheet. However, challenges include declining revenue growth and volatile cash flow trends, which need addressing for sustained long-term growth.

Income Statement

Mochida Pharmaceutical has shown a decline in revenue growth over the past few years, with a significant drop in the most recent year. Despite this, the company maintains healthy gross and net profit margins, indicating strong cost management and profitability. However, the declining revenue trend is a concern for future growth prospects.

Balance Sheet

The company has a very low debt-to-equity ratio, reflecting minimal leverage and a strong equity base. Return on equity has been stable, though slightly declining, indicating efficient use of equity to generate profits. The equity ratio is robust, suggesting financial stability and low risk.

Cash Flow

Mochida Pharmaceutical's cash flow performance is mixed. While the operating cash flow has improved recently, the free cash flow growth has been volatile. The free cash flow to net income ratio is strong, indicating good cash generation relative to earnings, but past negative free cash flow growth rates highlight potential cash flow management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	106.38B	105.16B	102.89B	103.26B	110.18B	103.00B
Gross Profit	54.46B	53.79B	52.07B	55.12B	59.55B	54.79B
EBITDA	11.20B	11.00B	8.97B	11.71B	17.28B	14.75B
Net Income	6.03B	5.68B	4.55B	6.65B	10.57B	8.59B
Balance Sheet
Total Assets	161.74B	160.12B	158.80B	158.83B	163.14B	161.79B
Cash, Cash Equivalents and Short-Term Investments	54.69B	51.15B	46.79B	60.51B	61.91B	63.49B
Total Debt	830.00M	342.00M	369.00M	190.00M	0.00	0.00
Total Liabilities	30.59B	29.43B	30.83B	32.06B	34.50B	34.82B
Stockholders Equity	131.15B	130.69B	127.97B	126.77B	128.64B	126.97B
Cash Flow
Free Cash Flow	0.00	7.19B	-9.78B	5.13B	4.36B	7.11B
Operating Cash Flow	0.00	9.35B	-7.48B	7.30B	7.46B	9.20B
Investing Cash Flow	0.00	17.36B	74.00M	-2.95B	-2.01B	-880.00M
Financing Cash Flow	0.00	-2.87B	-6.39B	-6.88B	-5.96B	-5.11B

Mochida Pharmaceutical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3090.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Negative. The current price of 3090 is above the 20-day moving average (MA) of 3066.00, below the 50-day MA of 3126.76, and above the 200-day MA of 3075.67, indicating a bearish trend. The MACD of -43.46 indicates Positive momentum. The RSI at 35.29 is Neutral, neither overbought nor oversold. The STOCH value of 10.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4534.

Mochida Pharmaceutical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4521	―	¥132.01B	11.07	8.77%	4.64%	31.19%	72.28%
4569	―	¥73.96B	7.84	―	3.70%	9.83%	86.18%
4553	―	¥139.47B	8.72	9.60%	2.82%	11.11%	-5.42%
4886	―	¥57.64B	12.11	―	2.48%	6.23%	-31.45%
4547	―	¥164.41B	13.91	5.93%	2.86%	15.40%	7.73%
4534	―	¥100.32B	17.35	4.88%	2.71%	2.74%	36.86%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Mochida Pharmaceutical Co., Ltd. Corporate Events

Mochida Pharmaceutical Acquires Stake in And Pharma to Boost Core Business

Mochida Pharmaceutical Co., Ltd. has announced its decision to acquire 20% of And Pharma Co., Ltd., making it an equity-method affiliate, as part of its strategy to enhance its core pharmaceutical business. This acquisition aims to create synergies by combining Mochida’s expertise in biosimilar development with And Pharma’s manufacturing capabilities, while also collaborating with Itochu Corporation to strengthen the business foundation of And Pharma’s subsidiaries. The move is expected to contribute to a stable supply of pharmaceuticals and support Japan’s medical economy by providing high-quality generics and biosimilars.

The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3460.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.

Mochida Pharmaceutical Reports Strong Q1 2025 Financial Results

Mochida Pharmaceutical Co., Ltd. reported a significant improvement in its financial performance for the three months ending June 30, 2025, with net sales increasing by 4.8% and profit attributable to owners of the parent rising by 21.8% compared to the previous year. The company’s strong financial results reflect its robust market positioning and operational efficiency, although it maintains a cautious outlook for the full fiscal year with modest growth forecasts.